Yes, always best to be cautious and selective. But he can cause movement in shares via his subscribers and it can be useful to be aware of that as an explanation of such movements. For example he advised this morning to move from one share to others with more short/medium term potential such as CPT and now Concepta has moved from negative to positive.
Lets up hes more on the ball here.
Last month he said buy SLE. i noticed posters also bullish on that stock post they wish he had not as it was the "kiss of death "
Not sure you should pay any head to him ?
He's upgraded this to a strong buy, expects this to double next year and possibly double again the following year. But he's annoyed that pi's didn't get in on the placing and that the RNS re income from the new order wasn't released ahead of the placing for a higher price.
Done well since was at about 11p on Aug tip TW claims they have shed loads .
They nearly doubled @ 21p before gradually falling back to today 17p.
Reckon they trade them.
one of his dragon den shares at his show last week.
Speculative Buy at 19.8p
Price Target: 26.0p
Human infertility is a critical but much neglected aspect of reproductive health. The World Health Organisation estimated in 2010 that 48.5 million couples worldwide were unable to conceive after five years of trying. It identifies a highly motivated target consumer group.
Recognising that global access to reproductive health has been defined as one of the United Nations Millennium Development Goals, Concepta is now uniquely able to provide women with an alternative means of assessment. MyLotus technology differentiates itself by collecting both quantitative and qualitative measurement of a womans personal hCG and LH hormone levels in urine, with a view to improving the probability of natural conception.
The product is market ready launching in China during Q42016, with EU regulatory approval expected to follow in 2017. The global opportunity addressed by Concepta is estimated to be worth as much as US$2 billion. Beyond which, its technology platform opens a much wider opportunity for personalised monitoring and self-diagnosis. Beaufort has completed a valuation of Concepta using both DCF and peer group assessments. These provide an average valuation of £28.4 million for the Group, which equates to a price target of 26.0p/share. SPECULATIVE BUY Read the full report
Beaufort Securities acts as corporate broker to Concepta Plc
Important message from the Financial Conduct Authority:
Posting inside information that is not public knowledge, or information that is false or misleading, may constitute market abuse.
This could lead to an unlimited fine and up to seven years in prison.
If you have any information, concerns or queries about market abuse, click here.
The content of the messages posted represents the opinions of the author, and does not represent the opinions of Interactive Investor Trading Limited or its affiliates and has not been approved or issued by Interactive Investor Trading Limited.
You should be aware that the other participants of the above discussion group are strangers to you and may make statements which may be misleading, deceptive or wrong.
Please remember that the value of investments or income from them may go down as well as up and that the past performance of an investment is not a guide to its performance in the future.
The discussion boards on this site are intended to be an information sharing forum and is not intended to address your particular requirements.
Whilst information provided on them can help with your investment research you need to consider carefully whether you should make (or refraining from making) investment or other decisions based on what you see without doing further research on investments you are interested in.
Participating in this forum cannot be a substitute for obtaining advice from an appropriate expert independent adviser who takes into account your circumstances and specific investment needs in selected investments that are appropriate for you.